Drug intelligence / Profile preview

Ganhuangcao

Development stage: Preclinical
Lead developer: Pharmesis International
Administration: Oral

Overview

Ganhuangcao refers to the traditional Chinese medicinal herb *Penthorum chinense Pursh*, which Pharmesis International utilizes as a raw material for its liver disease research and development pipeline. The company is engaged in preclinical research focused on isolating new active hepatoprotective components from this herb using advanced extraction technologies. Ganhuangcao is traditionally used in Chinese medicine to treat various liver conditions, including hepatitis B, hepatitis C, and alcoholic liver damage. It serves as the primary source for Pharmesis's "Gansu" (ATT) series of products. Research has identified polyphenols, particularly quercetin, as key active components within the herb that contribute to its hepatoprotective effects.

Other names: 赶黄草Penthorum chinense Pursh

Beyond the preview

Go deeper on Ganhuangcao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ganhuangcao.

Explore the full profile